Constructing a Novel Hypoxia-Inducible Bidirectional shRNA Expression Vector for Simultaneous Gene Silencing in Colorectal Cancer Gene Therapy

Cancer Biother Radiopharm. 2018 Apr;33(3):118-123. doi: 10.1089/cbr.2017.2401.

Abstract

Background: Nonspecific siRNA expression limits its application in cancer gene therapy. Therefore, a tightly regulated and reversibly inducible RNAi system is required to conditionally control the gene expression. This investigation aims at constructing a hypoxia/colorectal tumor dual-specific bidirectional short hairpin RNA (shRNA) expression vector.

Materials and methods: First, carcinoma embryonic antigen (CEA) promoter designed in two directions. Then, pRNA-bipHRE-CEA vector was constructed by insertion of the vascular endothelial growth factor enhancer between two promoters for hypoxic cancer-specific gene expression. To confirm the therapeutic effect of the dual-specific vector, two shRNA oligonucleotides were inserted in the downstream of each promoter. QRT-polymerase chain reaction and western blot assays were performed to estimate the mRNA and protein expression levels.

Results: Both mRNA and protein levels were significantly reduced (50%-60%) in the hypoxic colorectal cancer-treated cells when compared with the controls.

Conclusion: The novel bidirectional hypoxia-inducible shRNA expression vector may be efficient in colorectal cancer-specific gene therapy.

Keywords: CEA promoter; bidirectional promoter; colorectal cancer; shRNA; tumor hypoxia.

MeSH terms

  • Colorectal Neoplasms / genetics
  • Colorectal Neoplasms / therapy*
  • Gene Silencing*
  • Genetic Vectors / administration & dosage*
  • Humans
  • Hypoxia / genetics*
  • Promoter Regions, Genetic
  • Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors*
  • Proto-Oncogene Proteins c-bcl-2 / genetics
  • RNA, Small Interfering / genetics*
  • Tumor Cells, Cultured
  • beta Catenin / antagonists & inhibitors*
  • beta Catenin / genetics

Substances

  • BCL2 protein, human
  • CTNNB1 protein, human
  • Proto-Oncogene Proteins c-bcl-2
  • RNA, Small Interfering
  • beta Catenin